acoramidis (Attruby)

Indications

• transthyretin cardiac amyloidosis

Dosage

712 mg PO BID

Tablets: 356 mg

Adverse effects

• diarrhea & upper abdominal pain
• small decrease in eGFR ~ 7.5 mL/min

* adverse effects reversible with discontinuation

Mechanism of action

• oral TTR stabilzer
• acoramidis binds to transthyretin & stabilizes it, & inhibits its deposition as amyloid

Notes

• projected cost*: $19,000 for a 28-day supply

* trial participants continue to receive drug free for life

More general terms

• metabolic agent (metabolic modifier)
• heterocyclic compound, 1 ring

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71464713
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=135307127